If you knew there are easy, early treatments for COVID19, would you agree to be subjected to an experimental gene therapy? Probably not! The story of yet another suppressed early medical treatment that could have saved many lives now proven right by a clinical trial, published by Oxford University.
ER Doctor Richard Bartlett made waves last year with a viral video about his incredible success treating #Covid19 patients with a common asthma inhalant. After being vilified by the media and Fauci himself, recent studies, including one out of Oxford University, have validated his claim, stating that 90% of hospitalizations could have been avoided with this simple, early treatment.
The Oxford trial mentioned in the videos above entitled Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial was conducted because “Multiple early hospital cohorts of coronavirus disease 2019 (COVID-19) showed that patients with chronic respiratory disease were significantly under-represented. We hypothesised that the widespread use of inhaled glucocorticoids was responsible…”
“Conclusion Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery following early COVID-19 infection.” The study was funded by Oxford NIHR Biomedical Research Centre and AstraZeneca; ClinicalTrials.gov number, NCT04416399.
It is interesting to note that in the UK asthma sufferers are encouraged to believe they are at a grater risk and are now priority candidates for vaccination. Although the study mentioned above acknowledge a very different reality “patients with chronic respiratory disease were significantly under-represented”
